Loading patent…
OwnerMali Ketzinel Gilad, Esra Galun +3inventors
InventorsMali Ketzinel Gilad, Esra Galun, Leslie Mitchell, Eithan Galun, Verena Gauss-Mueller
Estimating the term…
A vaccine produced in edible plant and/or animal products, as well as a method of second-generation vaccine development through the production of at least one complete structure of a pathogen in a transgenic plant or animal is described. Preferably, the present invention enables the production of virus-like particles in edible food plants, through the co-expression of a plurality of proteins and/or of a plurality of portions of such proteins. The co-expression of viral structural proteins should enhance the immunogenicity of the transgenic antigen by providing all elements necessary to induce a protective immune response. In one variation of the method the immune response to the transgenic vaccine would be induced by presenting the transgenic proteins as part of an edible plant structure, utilizing this to stimulate the mucosal immune system. Alternatively, the vaccine produced in transgenic plant/animal products could be purified and used as an immunogen in other vaccination strategies. A corollary to this claim is the use of transgenic plant-derived viral vaccines as recombinant vectors to shuttle host or therapeutic genes to the liver or other tissues of the body utilizing the natural trophism of the virus. A second method of vaccination, that involves the stimulation of mucosal immunity, includes the use of conventional vaccines that are applied to the surface of the rectum to induce an immune response that is manifest both locally (in the intestinal mucosa) and systemically (blood and other body tissues).
A method for administering a viral vaccine to a subject, the viral vaccine being for a virus entering the subject through a gastrointestinal mucosa, wherein a target organ of the virus is not the intestine, the viral vaccine comprising an engineered viral particle, the engineered viral particle comprising a group of co-expressed plurality of viral proteins or portions thereof, wherein said group of co-expressed plurality of viral proteins or portions thereof is expressed in an edible plant material, the method comprising:
A method for delivering at least one viral encapsidated gene through a gastrointestinal mucosa of a subject, the at least one viral encapsidated gene being a Hepatitis A virus (HAV) gene, the method comprising:
A method for administering a viral vaccine for Hepatitis A virus (HAV) to a subject, wherein a target organ of HAV is the liver, the method comprising:
A vaccine against a disease-causing pathogen for administration to a subject, comprising:
The use of a vaccine against a virus, contained in an edible plant material, for oral administration to a subject, to protect the subject against the virus, wherein said edible material contains a plurality of co-expressed viral proteins or portions thereof.
An engineered viral vaccine, comprising:
An engineered viral vaccine, comprising:
A method for administering a viral vaccine for Hepatitis A virus (HAV) to a subject, wherein a target organ of HAV is the liver, the method comprising:
A method for administering a viral vaccine for Hepatitis A virus (HAV) to a subject, the method comprising:
A method for administering a viral vaccine for Hepatitis A virus (HAV) to a subject, the method comprising:
A method for preparing a vaccine against a disease-causing pathogen for administration to a subject, the method comprising:
Dependencies are inferred from the claim text.